ORYZON Announces U.S. Patent Grant for Vafidemstat in Borderline Personality Disorder (BPD)
MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The granted claims cover methods of treating non-aggressive symptoms of borderline personality disorder (BPD) using LSD1 inhi
MADRID and CAMBRIDGE, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,673,044, entitled “Methods of treating borderline personality disorder”. The granted claims cover methods of treating non-aggressive symptoms of borderline personality disorder (BPD) using LSD1 inhibitors, including vafidemstat, complementing Oryzon’s patent portfolio covering the treatment of aggression.
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.